HK1206025A1 - Thiophene miazines derivate, preparation method therefor, and medical application thereof - Google Patents

Thiophene miazines derivate, preparation method therefor, and medical application thereof

Info

Publication number
HK1206025A1
HK1206025A1 HK15106672.5A HK15106672A HK1206025A1 HK 1206025 A1 HK1206025 A1 HK 1206025A1 HK 15106672 A HK15106672 A HK 15106672A HK 1206025 A1 HK1206025 A1 HK 1206025A1
Authority
HK
Hong Kong
Prior art keywords
miazines
derivate
thiophene
preparation
method therefor
Prior art date
Application number
HK15106672.5A
Other languages
Chinese (zh)
Inventor
李心
孫飄揚
蘭炯
彭建彪
陳陽
王斌
董慶
Original Assignee
Shanghai Hengrui Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Hengrui Pharm Co Ltd filed Critical Shanghai Hengrui Pharm Co Ltd
Publication of HK1206025A1 publication Critical patent/HK1206025A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK15106672.5A 2013-05-17 2015-07-13 Thiophene miazines derivate, preparation method therefor, and medical application thereof HK1206025A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201310183029 2013-05-17
PCT/CN2014/075387 WO2014183520A1 (en) 2013-05-17 2014-04-15 Thiophene miazines derivate, preparation method therefor, and medical application thereof

Publications (1)

Publication Number Publication Date
HK1206025A1 true HK1206025A1 (en) 2015-12-31

Family

ID=51897671

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15106672.5A HK1206025A1 (en) 2013-05-17 2015-07-13 Thiophene miazines derivate, preparation method therefor, and medical application thereof

Country Status (4)

Country Link
CN (1) CN104470921B (en)
HK (1) HK1206025A1 (en)
TW (1) TWI642667B (en)
WO (1) WO2014183520A1 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016015597A1 (en) * 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. Compounds as cdk small-molecule inhibitors and uses thereof
CN105622638B (en) * 2014-10-29 2018-10-02 广州必贝特医药技术有限公司 Pyrimidine or pyridopyridine ketone compounds and its preparation method and application
CA2974021A1 (en) 2015-02-03 2016-08-11 Jiangsu Hengrui Medicine Co., Ltd. Hydroxyethyl sulfonate of cyclin-dependent protein kinase inhibitor, crystalline form thereof and preparation method therefor
WO2016169422A1 (en) * 2015-04-22 2016-10-27 江苏恒瑞医药股份有限公司 Crystal form of a cyclin-dependent kinase inhibitor and the preparation method thereof
CN106065016B (en) * 2015-04-22 2019-03-12 江苏恒瑞医药股份有限公司 A kind of crystal form and preparation method thereof of cyclin dependent kinase inhibitor
CN105130986B (en) * 2015-09-30 2017-07-18 广州科擎新药开发有限公司 Pyrimidine or pyridopyridine ketone compounds and its application
CN108699055B (en) * 2015-12-13 2020-10-23 杭州英创医药科技有限公司 Heterocyclic compounds as anti-cancer agents
WO2017133542A1 (en) * 2016-02-04 2017-08-10 江苏恒瑞医药股份有限公司 Pharmaceutical composition comprising pyridopyrimidine derivative or pharmaceutically acceptable salt thereof
CN107028899B (en) * 2016-02-04 2021-07-02 江苏恒瑞医药股份有限公司 Pharmaceutical composition containing pyridopyrimidine derivatives or pharmaceutically acceptable salts thereof
CN107137408A (en) * 2016-03-01 2017-09-08 江苏恒瑞医药股份有限公司 A kind of CDK4/6 inhibitor combines the purposes in the medicine for preparing treatment breast cancer with arimedex
CN107137409A (en) * 2016-03-01 2017-09-08 江苏恒瑞医药股份有限公司 A kind of CDK4/6 inhibitor combines the purposes in the medicine for preparing treatment breast cancer with estrogen receptor antagon
WO2017161253A1 (en) 2016-03-18 2017-09-21 Tufts Medical Center Compositions and methods for treating and preventing metabolic disorders
CN105777749A (en) * 2016-04-06 2016-07-20 中国药科大学 Pyridopyrimidine compound and preparation method and application thereof
KR102290815B1 (en) * 2016-11-28 2021-08-18 데이진 화-마 가부시키가이샤 Pyrido[3,4-d]pyrimidine derivatives and pharmaceutically acceptable salts thereof
US10676474B2 (en) * 2016-12-16 2020-06-09 Cstone Pharmaceuticals 1,6-naphthyridine derivatives as CDK4/6 inhibitor
CN108794452B (en) 2017-05-05 2021-05-28 上海时莱生物技术有限公司 Compound with kinase inhibition activity, preparation method and application thereof
TW201904574A (en) * 2017-06-21 2019-02-01 大陸商江蘇恆瑞醫藥股份有限公司 Use of SERD and CDK4/6 inhibitors, PI3K/mTOR pathway inhibitors
CN109384767B (en) * 2017-08-08 2020-05-05 江苏恒瑞医药股份有限公司 Preparation method and intermediate of pyridopyrimidine derivative
CN109867667B (en) * 2017-12-05 2021-06-11 中国药科大学 PARP and PI3K dual-target inhibitors containing pyridopyrimidine structure
JP2021521282A (en) 2018-04-24 2021-08-26 上海海雁医薬科技有限公司Ｓｈａｎｇｈａｉ Ｈａｉｙａｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．， Ｌｔｄ． CDK4 / 6 inhibitors, their pharmaceutically acceptable salts and crystalline polymorphs, and their applications
CN111818925B (en) * 2018-05-23 2023-12-12 江苏恒瑞医药股份有限公司 Use of CDK4/6 inhibitors in combination with EGFR inhibitors for the preparation of a medicament for the treatment of tumour diseases
CN110680919A (en) * 2018-07-06 2020-01-14 江苏恒瑞医药股份有限公司 Application of CDK4/6 inhibitor in preparation of medicine for treating tumors in combination with immunotherapy
US10857146B2 (en) 2018-08-21 2020-12-08 Jiangsu Hengrui Medicine Co., Ltd. Method for preventing or treating tumor diseases with a combination of tyrosine kinase inhibitor and CDK4/6 inhibitor
CN112955148B (en) * 2018-12-13 2022-11-22 江苏恒瑞医药股份有限公司 Use of CDK4/6 inhibitors in combination with immunotherapy for the preparation of a medicament for the treatment of lymphoma
JP2022523088A (en) 2019-01-30 2022-04-21 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 Use of compositions containing CDK4 / 6 inhibitors in combination with anastrozole in the preparation of drugs for the treatment of neoplastic diseases
WO2020239051A1 (en) * 2019-05-30 2020-12-03 江苏恒瑞医药股份有限公司 Uses of cdk4/6 inhibitor jointly with vegfr inhibitor in preparing tumor-treating medicament
TW202114685A (en) * 2019-06-20 2021-04-16 大陸商江蘇恒瑞醫藥股份有限公司 Pharmaceutical composition and preparation method thereof
CN110143948B (en) * 2019-06-21 2021-05-14 上海博悦生物科技有限公司 CDK4/6 inhibitor, pharmaceutical composition, preparation method and application thereof
TW202114689A (en) * 2019-08-06 2021-04-16 大陸商江蘇恒瑞醫藥股份有限公司 Use of combination of cdk4/6 inhibitor and multi-target tyrosine kinase inhibitor in preparation of medicine for treating tumor
WO2021047573A1 (en) * 2019-09-11 2021-03-18 江苏恒瑞医药股份有限公司 Use of mek inhibitor in combination with cdk4/6 inhibitor in preparation of drugs for treating tumors
WO2021063332A1 (en) * 2019-09-30 2021-04-08 江苏恒瑞医药股份有限公司 Use of ezh2 inhibitor combined with cdk4/6 inhibitor in preparation of drug for treating tumor
CN110540535B (en) * 2019-10-23 2020-07-31 上海再启生物技术有限公司 Process suitable for preparing 4- (6-aminopyridin-3-yl) substituted piperidine in amplification way
WO2022113003A1 (en) 2020-11-27 2022-06-02 Rhizen Pharmaceuticals Ag Cdk inhibitors
CN112778303A (en) * 2020-12-31 2021-05-11 武汉九州钰民医药科技有限公司 Preparation method of CDK4/6 kinase inhibitor SHR6390
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors
TW202317135A (en) * 2021-07-13 2023-05-01 大陸商江蘇恒瑞醫藥股份有限公司 Use of selective estrogen receptor covalent antagonists in combination with cdk4/6 inhibitors in the preparation of medicaments for the treatment of breast cancer
CN114456180B (en) * 2022-02-18 2023-07-25 贵州大学 Compounds and pharmaceutical formulations for the treatment and/or prophylaxis of malignant tumors and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1470124T3 (en) * 2002-01-22 2006-04-18 Warner Lambert Co 2- (Pyridin-2-yl amino) pyrido [2,3] pyrimidin-7-one
KR20090052385A (en) * 2006-09-08 2009-05-25 화이자 프로덕츠 인크. Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
EP2142543B8 (en) * 2007-04-11 2013-07-03 Exelixis, Inc. Pyrido [2, 3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
MX2010012703A (en) * 2008-05-21 2010-12-21 Ariad Pharma Inc Phosphorous derivatives as kinase inhibitors.
JP2012504645A (en) * 2008-10-01 2012-02-23 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル Pharmaceutical composition for reducing or preventing the influence of ionizing radiation on healthy cells
WO2011156786A2 (en) * 2010-06-10 2011-12-15 Afraxis, Inc. 6-(ethynyl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
CN103012399B (en) * 2012-11-22 2015-06-17 中国科学院广州生物医药与健康研究院 7-oxopyridinopyrimidine compound as well as medicinal composition and application thereof

Also Published As

Publication number Publication date
CN104470921A (en) 2015-03-25
TW201444838A (en) 2014-12-01
TWI642667B (en) 2018-12-01
WO2014183520A1 (en) 2014-11-20
CN104470921B (en) 2017-05-03

Similar Documents

Publication Publication Date Title
HK1206025A1 (en) Thiophene miazines derivate, preparation method therefor, and medical application thereof
HRP20170888T1 (en) Tubulysin compounds, methods of making and use
HK1203317A1 (en) Edible composition, preparation method and use thereof
EP2953012A4 (en) Electronic skin, preparation method and use thereof
EP2968304A4 (en) 4-phenylpiperidines, their preparation and use
HK1222778A1 (en) Medical device, and the methods of using same
GB202005994D0 (en) Patient interface and aspects thereof
EP2968303A4 (en) Octahydrocyclopentapyrroles, their preparation and use
EP3088353A4 (en) Bilirubin nanoparticle, use thereof, and preparation method therefor
HK1203398A1 (en) Edible composition, preparation method and use thereof
HK1225993A1 (en) Compound of glycosaminoglycan, preparation method and use thereof
ZA201601343B (en) Vancomycin derivative, and preparation method and application thereof
HK1218120A1 (en) Tricyclic benzoxaborole compound, preparation method therefor, and use thereof
HK1203397A1 (en) Edible composition, preparation method and use thereof
EP2813495A4 (en) 2-arylbenzofuran-7-formamide compounds, preparation method and use thereof
HK1206329A1 (en) Phenol derivative, method of preparing same, and pharmaceutical application of same
EP2952519A4 (en) Protopanoxadiol derivative, preparation method thereof and application thereof
EP3078659A4 (en) 3-furyl-2-cyano-2-acrylamide derivative, preparation method therefor, pharmaceutical composition and use thereof
EP3006432A4 (en) 2,3-butanediamide epoxide compound and preparation method and use thereof
ZA201603990B (en) Taxane compound, and preparation method and use thereof
ZA201600015B (en) Anti-fibrogenic compounds, methods and uses thereof
EP2987794A4 (en) Vinblastine derivatives, preparation method therefor and application thereof
EP2980096A4 (en) 2 ,3 ,5 -trihydroxy-androst-6-one and preparation methods and use thereof
GB201315887D0 (en) Medical applicator
ZA201603682B (en) Taxanes compounds, preparation method therefor, and uses thereof